Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04119102 · ClinicalTrials.gov registry record · Phase 4
Duobrii in Combination With Biologics
A Phase 4 study of Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04119102 is a Phase 4 study of Psoriasis that is actively recruiting participants, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 25 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04119102, a Phase 4 study of Psoriasis, is actively recruiting participants, sponsored by Psoriasis Treatment Center of Central New Jersey.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Conditions Studied
Interventions
- DRUG Duobrii
Study Locations (1)
New Jersey
- Psoriasis Treatment Center of Central New Jersey - East Windsor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2020-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04119102
The ClinicalTrials.gov registry entry for NCT04119102 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (95% lower). The listed sponsor is Psoriasis Treatment Center of Central New Jersey, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Duobrii is the first listed.
NCT04119102 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04119102 about?
NCT04119102 is a clinical study titled "Duobrii in Combination With Biologics". 12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
What is the current status of trial NCT04119102?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2019-10-14. Estimated completion is 2020-09-01.
What conditions does trial NCT04119102 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT04119102?
The interventions under investigation include: Duobrii (DRUG).
Who is sponsoring clinical trial NCT04119102?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04119102 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.